Seminomas, which account for -40% (27-71%) of testicular cancers, generally tend to present as local (Stage I) or locoregional (Stage II) disease in 70-90% of the patients (Calman et al., 1979; Dixon & Moore, 1952; Maier et al., 1968; Mostofi, 1973; Thomas et al., 1982) . Orchiectomy and retroperitoneal radiotherapy in Stage I and minimal Stage II disease usually result in an excellent overall prognosis, with 5-year survival rates approaching 90%. However, long-term results have remained rather poor with up to 40-50% relapses when radiotherapy served as the sole treatment of bulky Stage II disease (Ball et al., 1982; Smith et al., 1979; Thomas et al., 1982) .
Besides some early trials reporting on the sensitivity of metastatic seminomas to single agent chemotherapy, recent studies, mostly utilizing cisplatin containing regimens originally employed for the treatment of nonseminomatous testicular cancer have described a 50-70% or even higher complete remission rate (Ball et al., 1982; Mendenhall et al., 1981; Vugrin & Whitmore, 1984) . However, most series contained only a small number of patients, thereby precluding any definitive conclusion on the value of the regimens used. In addition, significant toxicity, predominantly occurring in previously irradiated patients, has been observed with most of these regimens. Nevertheless, cytostatic chemotherapy appears to be the treatment of choice not only for widespread metastatic, but also for bulky retroperitoneal disease. In the present retrospective analysis, the efficacy and toxicity of different combination chemotherapies in the treatment of advanced disseminated seminomas has been studied.
Materials and methods

Patients
This report includes 28 patients with histologically confirmed pure seminoma of the testis who presented at our institution between 1977 and 1983. None of these patients had received prior chemotherapy. Patient characteristics are shown in Table I Scheulen et al., 1980; Schuette et al., 1983) . Treatment schedules and doses are shown in Table II . Two patients received the 3-drug combination of cisplatin, vinblastine and bleomycin (Einhorn & Donohue, 1979) . Since 1980/81, mainly in the lights of some favourable results of early Phase II trials, chemotherapy of seminomas primarily consisted of ifosfamide, either alone or in combination with etoposide or cisplatin. Most patients received at least 4 courses (range: 4-9) of the fractionated chemotherapy with either regimen. Generally, treatment was repeated for at least 2 courses after the induction of complete remission. (Table IV) . Toxicity Side effects usually included alopecia and myelosuppression (Table VI) . Significant reductions of the standard cytostatic dosages were necessary in almost all patients after prior irradiation. Platelet transfusions and antibiotic treatment for severe thrombo-and leukocytopenia were required in one patient after PVB chemotherapy. Temporary increases of serum creatinine concentrations were observed in two patients after PVB and ifosfamide/cisplatin, respectively. Long-lasting neurotoxic side effects due to vinblastine (and cisplatin) became apparent in one patient after sequentially alternating chemotherapy with vinblastine/bleomycin and cisplatin/adriamycin. Interstitial lung fibrosis after a total dose of 300 mg of bleomycin occurred in a 43-year old patient who had previously received mediastinal irradiation. One patient developed a paralytic subileus after PVB. Nausea and vomiting usually occurred during cisplatin therapy but were significantly less intense and only (Blokhin et al., 1958; Chebotareva, 1964; Golbey, 1970; Mackenzie, 1966; Monfardini et al., 1972; Vugrin et al., 1981; Whitmore et al., 1977) . However, since only 5-15% of patients initially present with advanced locoregional or disseminated disease and only few patients relapse after prior radiotherapy of minimal retroperitoneal disease, most trials include only small numbers of patients (Table VII) . So far, chemotherapy with cisplatin, vinblastine and bleomycin (PVB) has been the most widely used combination resulting in a 50-70% CR rate with most CR patients remaining free of disease (Einhorn & Williams, 1980) . Nevertheless, significant morbidity preferably occurring after prior radiotherapy has been observed by several authors (Ball et al., 1982; Mendenhall et al., 1981; Wajsman et al., 1983) .
The present series including 28 patients with widespread metastatic and/or advanced retroperitoneal seminoma has demonstrated an excellent chemosensitivity with 23/28 (82%) patients being currently free of disease after a median follow-up of 28 + months. Thus, in comparison to the 30-50% actual long-term survival rates (median followup .2 years) described for patients with similar stages of advanced and bulky nonseminomatous testicular cancer, disseminated seminoma in our experience appears to be the germ cell cancer most responsive to cytostatic chemotherapy (Einhorn & Donohue, 1979; Vugrin et al., 1982) . At present, no substantial data are available to suggest therapeutic benefit from consolidating radiotherapy in complete responders. In this series, relapse occurred in one of 8 patients with and in one of 11 patients without additional irradiation.
Similar to other reports, adjuvant retroperitoneal lymph node dissection after chemotherapy as carried out in 6/14 of the initially ,B-hCG positive, bulky disease patients might be of only limited value since microscopic tumour residues were discovered in none of these patients (Vugrin & Whitmore, 1984; Samuels et al., 1980) . In addition, complete lymphadenectomy was difficult to perform because of the apparently dense fibrous tissue found in the retroperitoneal area. Surgical complications, however, did not occur.
In accordance with the results of several radiotherapeutic trials, moderate elevation of P-hCG levels, although suggesting the presence of nonseminomatous, chorionic tumour elements, did not seem, in our patients to adversely influence the response and survival rates as compared to serologically negative patients (Ball et al., 1982; Javadpour et al., 1978; Mauch et al., 1979) . The treatment failures observed in ,B-hCG positive patients might be due to the more advanced stage of disease and/or prior irradiation.
In conclusion, the present series substantiates the role of combination chemotherapy in advanced seminoma. Since 80-90% of all relapses have been shown to occur within 2-3 years after remission induction, most of our complete responders probably might attain continuous CR (Calman et al., 1979; Thomas et al., 1982) . However, with respect to the limited number of patients and the retrospective design of this analysis, no definite conclusions can yet be made on the therapeutic superiority of any one of the different chemotherapeutic regimens used. Nevertheless, this preliminary experience suggests that the combination of ifosfamide and etoposide or cisplatin may prove equally effective and, most importantly, less toxic as compared to the conventional simultaneous or sequentially alternating PVB + A chemotherapy.
